LATLUMTOX Laboratory, Bron, France.
Rapid Commun Mass Spectrom. 2024 Apr 15;38(7):e9711. doi: 10.1002/rcm.9711.
Hexahydrocannabinol (HHC), a compound derived from synthetic production using cannabidiol (CBD) or delta-9-tetrahydrocannabinol (Δ -THC), has gained recent attention due to its presence in seized materials across Europe. Sold legally in various forms, HHC poses potential health risks, particularly as a legal alternative to THC in some countries. Despite its historical description in the 1940s, limited toxicology data, pharmacological understanding, and analytical methods for HHC exist.
This study proposes analytical techniques using mass spectrometry to detect, identify, and quantify (9R)-HHC and (9S)-HHC, concurrently with THC and CBD in various matrices, including oral fluid, whole blood, and seized material. Three distinct methods were employed for different matrices: GC/MS for seized material, GC/MS/MS for whole blood, and UHPLC/MS/MS for oral fluid. Methods were validated qualitatively for oral fluid with a FLOQSwab® device and quantitatively in whole blood and seized material according to Peters et al's recommendations and ICH guidelines.
Validated methods were considered reliable in detecting and quantifying HHC isomers in terms of repeatability, reproducibility, and linearity with r systematically >0.992. These methods were applied to authentic cases, including seized materials and biological samples from traffic control (whole blood and oral fluid). In seized materials, (9R)-HHC levels ranged from 2.09% to 8.85% and (9R)-HHC/(9S)-HHC ratios varied from 1.36 to 2.68. In whole blood sample, (9R)-HHC and (9S)-HHC concentrations were, respectively, 2.38 and 1.39 ng/mL. For all analyzed samples, cannabinoids such as THC and CBD were also detected.
This research contributes analytical insights into differentiating and simultaneously analyzing (9R)-HHC and (9S)-HHC, using widely applicable mass spectrometric methods. The study emphasizes the need for vigilance among toxicologists, as new semisynthetic cannabinoids continue to emerge in Europe, with potential health implications. The findings underscore the importance of reliable analytical methods for monitoring these compounds in forensic and clinical settings.
六氢大麻酚(HHC)是一种源自大麻二酚(CBD)或Δ-9-四氢大麻酚(Δ-THC)的合成产物,由于在欧洲缴获的物质中存在该物质而受到关注。HHC 以各种形式合法销售,可能对健康造成风险,特别是在一些国家被视为 THC 的合法替代品。尽管 HHC 在 20 世纪 40 年代就有历史描述,但目前仅有有限的毒理学数据、药理学理解和用于 HHC 的分析方法。
本研究提出了使用质谱检测、鉴定和定量(9R)-HHC 和(9S)-HHC 的分析技术,同时检测各种基质中的 THC 和 CBD,包括口服液、全血和缴获的材料。三种不同的方法适用于不同的基质:GC/MS 用于缴获材料,GC/MS/MS 用于全血,UHPLC/MS/MS 用于口服液。根据 Peters 等人的建议和 ICH 指南,使用 FLOQSwab®设备对口服液进行定性验证,对全血和缴获材料进行定量验证。
所验证的方法在检测和定量 HHC 异构体方面被认为是可靠的,在重复性、再现性和线性方面,r 值均大于 0.992。这些方法应用于真实案例,包括缴获的材料和交通管制中的生物样本(全血和口服液)。缴获材料中的(9R)-HHC 水平在 2.09%至 8.85%之间,(9R)-HHC/(9S)-HHC 比值在 1.36 至 2.68 之间。在全血样本中,(9R)-HHC 和(9S)-HHC 的浓度分别为 2.38 和 1.39ng/mL。所有分析的样本中还检测到了大麻素如 THC 和 CBD。
本研究使用广泛适用的质谱方法为区分和同时分析(9R)-HHC 和(9S)-HHC 提供了分析见解。该研究强调了毒理学家保持警惕的必要性,因为新的半合成大麻素继续在欧洲出现,可能对健康产生影响。研究结果强调了在法医和临床环境中监测这些化合物时使用可靠分析方法的重要性。